These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16363888)

  • 1. Solifenacin in overactive bladder syndrome: a viewpoint by Scott Serels.
    Serels S
    Drugs Aging; 2005; 22(12):1070-1. PubMed ID: 16363888
    [No Abstract]   [Full Text] [Related]  

  • 2. Solifenacin in overactive bladder: a viewpoint by Hashim Hashim.
    Hashim H
    Drugs Aging; 2005; 22(12):1070. PubMed ID: 16363889
    [No Abstract]   [Full Text] [Related]  

  • 3. The emerging role of solifenacin in the treatment of overactive bladder.
    Robinson D; Cardozo L
    Expert Opin Investig Drugs; 2004 Oct; 13(10):1339-48. PubMed ID: 15461562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence.
    Kelleher C; Cardozo L; Kobashi K; Lucente V
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Jun; 17(4):382-8. PubMed ID: 16283422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solifenacin in overactive bladder syndrome.
    Simpson D; Wagstaff AJ
    Drugs Aging; 2005; 22(12):1061-9. PubMed ID: 16363887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solifenacin and darifenacin for overactive bladder.
    Obstet Gynecol; 2005 Aug; 106(2):401-2. PubMed ID: 16055596
    [No Abstract]   [Full Text] [Related]  

  • 7. Solifenacin versus tolterodine--a head-to-head study: finally! But not final?
    Staskin DR; Dmochowski RR; Wein AJ
    Curr Urol Rep; 2005 Nov; 6(6):403-4. PubMed ID: 16238911
    [No Abstract]   [Full Text] [Related]  

  • 8. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.
    Cardozo L; Castro-Diaz D; Gittelman M; Ridder A; Huang M
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):512-9. PubMed ID: 16625311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine.
    Kershen RT; Hsieh M
    Curr Urol Rep; 2004 Oct; 5(5):359-67. PubMed ID: 15461912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status.
    Toglia MR; Ostergard DR; Appell RA; Andoh M; Fakhoury A; Hussain IF
    Int Urogynecol J; 2010 Jul; 21(7):847-54. PubMed ID: 20339833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder].
    Ohtake A; Sato S; Ikeda K; Sasamata M; Miyata K
    Nihon Yakurigaku Zasshi; 2006 Dec; 128(6):425-32. PubMed ID: 17167217
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
    Jonas U; Rackley RR
    Eur Urol; 2006 Jan; 49(1):187-8; author reply 188-90. PubMed ID: 16310930
    [No Abstract]   [Full Text] [Related]  

  • 13. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
    Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
    J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solifenacin.
    Kreder KJ
    Urol Clin North Am; 2006 Nov; 33(4):483-90, ix. PubMed ID: 17011384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Urinary incontinence: new pharmacologic therapies].
    Robles García JE; Zudaire Bergera JJ; Rosell Costa D; Berián Polo JM
    Rev Med Univ Navarra; 2004; 48(4):43-9. PubMed ID: 15812946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective open label study of solifenacin for overactive bladder in children.
    Bolduc S; Moore K; Nadeau G; Lebel S; Lamontagne P; Hamel M
    J Urol; 2010 Oct; 184(4 Suppl):1668-73. PubMed ID: 20728124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg.
    Cornu JN
    Eur Urol; 2013 Jul; 64(1):82-3. PubMed ID: 23398768
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.
    Chapple CR; Martinez-Garcia R; Selvaggi L; Toozs-Hobson P; Warnack W; Drogendijk T; Wright DM; Bolodeoku J;
    Eur Urol; 2005 Sep; 48(3):464-70. PubMed ID: 15990220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.